Financial Contrast: Petros Pharmaceuticals (NASDAQ:PTPI) versus MindWalk (NASDAQ:HYFT)

MindWalk (NASDAQ:HYFT) and Petros Pharmaceuticals (NASDAQ:PTPI) are both small-cap manufacturing companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, dividends, earnings, institutional ownership, risk and profitability.

Valuation & Earnings

This table compares MindWalk and Petros Pharmaceuticals”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MindWalk	$17.59 million	4.07	-$21.69 million	($0.20)	-7.75
Petros Pharmaceuticals	$5.11 million	0.04	-$8.16 million	($1.64)	0.00

Petros Pharmaceuticals has lower revenue, but higher earnings than MindWalk. MindWalk is trading at a lower price-to-earnings ratio than Petros Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares MindWalk and Petros Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MindWalk	-66.79%	-69.37%	-39.74%
Petros Pharmaceuticals	N/A	-78.22%	-23.50%

Institutional & Insider Ownership

6.7% of MindWalk shares are held by institutional investors. Comparatively, 12.3% of Petros Pharmaceuticals shares are held by institutional investors. 6.8% of MindWalk shares are held by company insiders. Comparatively, 8.2% of Petros Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings for MindWalk and Petros Pharmaceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MindWalk	1	1	2	1	2.60
Petros Pharmaceuticals	0	0	0	0	0.00

MindWalk currently has a consensus price target of $5.00, suggesting a potential upside of 222.58%. Given MindWalk’s stronger consensus rating and higher possible upside, equities research analysts clearly believe MindWalk is more favorable than Petros Pharmaceuticals.

Volatility and Risk

MindWalk has a beta of 0.79, meaning that its share price is 21% less volatile than the S&P 500. Comparatively, Petros Pharmaceuticals has a beta of 1.87, meaning that its share price is 87% more volatile than the S&P 500.

Summary

MindWalk beats Petros Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

About MindWalk

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation. The company has research collaboration agreements with Pierre Fabre S.A for antibody discovery; and Elektrofi, Inc. to explore a high-concentration formulation of COVID-19 antibody cocktail, PolyTope TATX-03. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada.

About Petros Pharmaceuticals

Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. The company offers men's health products, including vacuum erection devices, penile injections, PreBoost, VenoSeal, and urinary tract infection tests for the treatment of erectile dysfunction. Petros Pharmaceuticals, Inc. is based in New York, New York.